Cargando…

Management of immune checkpoint inhibitor‐related rheumatic adverse events

Immune checkpoint inhibitors (ICIs), which target the programmed cell death receptor‐1 and cytotoxic T lymphocyte‐associated antigen‐4 signaling pathways, represent remarkable breakthroughs in cancer treatment and have improved survival among patients with a variety of malignancies. However, the wid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Jiaxin, Wang, Hanping, Guo, Xiaoxiao, Wang, Qian, Duan, Lian, Si, Xiaoyan, Zhang, Li, Liu, Xiaowei, Li, Yue, Zhang, Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2019
Materias:	Clinical Guidelines
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938753/ https://www.ncbi.nlm.nih.gov/pubmed/31762209 http://dx.doi.org/10.1111/1759-7714.13249

Ejemplares similares

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
por: Zhuang, Junling, et al.
Publicado: (2020)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
por: Wang, Hanping, et al.
Publicado: (2019)

Clinical diagnosis and treatment of immune checkpoint inhibitors‐related endocrine dysfunction
por: Duan, Lian, et al.
Publicado: (2020)

Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
por: Guo, Xiaoxiao, et al.
Publicado: (2019)

Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections
por: Lu, Minya, et al.
Publicado: (2020)

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
por: Liu, Xiaowei, et al.
Publicado: (2020)

Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events
por: Zheng, Ke, et al.
Publicado: (2020)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
por: Li, Yue, et al.
Publicado: (2020)

Use of glucocorticoids in the management of immunotherapy‐related adverse effects
por: Wang, Hanping, et al.
Publicado: (2020)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
por: Si, Xiaoyan, et al.
Publicado: (2020)

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events
por: Song, Peng, et al.
Publicado: (2020)

Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
por: Xiao, Yan, et al.
Publicado: (2020)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related adverse reactions in the nervous system
por: Shi, Jiayu, et al.
Publicado: (2019)

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
por: Guidon, Amanda C, et al.
Publicado: (2021)

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
por: Wang, Wenxian, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
por: Brahmer, Julie R, et al.
Publicado: (2021)

Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
por: Zeng, Li, et al.
Publicado: (2023)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
por: Naidoo, Jarushka, et al.
Publicado: (2023)

Rheumatic Immune-Related Adverse Events—A Consequence of Immune Checkpoint Inhibitor Therapy
por: Bobircă, Anca, et al.
Publicado: (2021)

Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
por: Reynolds, Kerry L, et al.
Publicado: (2021)

Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis
por: Zhang, Shuo, et al.
Publicado: (2021)

Clinical recommendations for perioperative immunotherapy‐induced adverse events in patients with non‐small cell lung cancer
por: Ni, Jun, et al.
Publicado: (2021)

Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update
por: Dang, Quang Minh, et al.
Publicado: (2023)

Recommendations on SARS-CoV-2 Vaccination in Adult Patients with Rheumatic Diseases
por: Shen, Min, et al.
Publicado: (2021)

A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre
por: Cheema, Parneet K., et al.
Publicado: (2022)

Rheumatic Immuno-related Adverse Events following Immunotherapy with Checkpoint Inhibitors: Adverse Drug Reaction, or Other?
por: Manzo, Ciro
Publicado: (2021)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID‐19 epidemic
por: Zhao, Zhe, et al.
Publicado: (2020)

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors
por: Li, Jian, et al.
Publicado: (2018)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
por: Song, Peng, et al.
Publicado: (2020)

Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids
por: Russell, Mark D, et al.
Publicado: (2022)

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
por: Kostine, Marie, et al.
Publicado: (2021)

Strategies for improving the management of immune-related adverse events
por: Naing, Aung, et al.
Publicado: (2020)

Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis
por: Clemente Garulo, Daniel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3agtms4cobc3e42h1ousrr660f